Risk factors and outcomes of new-onset atrial fibrillation in patients hospitalized in an internal medicine ward: a case–control study
- 9 Downloads
Atrial fibrillation (AF) is a frequent pathology in Internal Medicine departments. The aim of our study was to identify the risk factors associated with the development of new-onset AF during hospitalization and to evaluate its outcome as in-hospital mortality. We conducted a retrospective case–control study on a cohort of 14,179 patients admitted to an internal medicine department. We included in the study the patients who did not have an anamnestic history of AF, who presented a sinus rhythm at the time of admission and who developed a new-onset AF during hospitalization. For each of these cases, two controls were enrolled who were not affected by AF. The patients included in the study were 588, including 196 cases and 392 controls. Patients who developed AF during hospitalization had significantly more comorbidity than controls. The most frequent causes for hospitalization were sepsis, significantly higher in the case group. From the results of the multivariate analysis, the factors related independently to the development of AF were the presence of a number of comorbidities ≥ 3 (OR = 1.52; p = 0.017), sepsis as a reason of hospitalization (OR = 2, 16; p = 0.001) and glycemic value at the admission ≥ 130 mg/dL (OR = 1.44; p = 0.047). Both the length of hospital stay and in-hospital mortality were higher in the group of patients who developed AF, with a statistically significant difference compared to controls (p < 0.001).
KeywordsNew-onset atrial fibrillation Atrial fibrillation Risk factors Hospitalized patients
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
All the procedures performed in this study were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
This is a retrospective study that include anonymized patients extracted from hospital database; data are presented aggregated and anonymously. No informed consent was taken.
- 1.Shinagawa K, Shi Y-F, Tardif J-C, Leung T-K, Nattel S (2002) Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 105(22):2672–2678. https://doi.org/10.1161/01.cir.0000016826.62813.f5 CrossRefGoogle Scholar
- 6.Lloyd-Jones DM, Wang TJ, Leip EP et al (2004) Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110(9):1042–1046. https://doi.org/10.1161/01.CIR.0000140263.20897.42 CrossRefGoogle Scholar
- 17.Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A et al (2012) Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33(19):2451–2496. https://doi.org/10.1093/eurheartj/ehs109 CrossRefGoogle Scholar
- 18.Nishimura RA, Otto CM, Bonow RO et al (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(23):2440–2492. https://doi.org/10.1161/CIR.0000000000000029 CrossRefGoogle Scholar
- 19.Allessie MA, de Groot NMS, Houben RPM et al (2010) Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation. Circ Arrhythm Electrophysiol 3(6):606–615. https://doi.org/10.1161/CIRCEP.109.910125 CrossRefGoogle Scholar
- 20.Alessandri N, Tufano F, Petrassi M et al (2009) Atrial fibrillation in pure rheumatic mitral valvular disease is expression of an atrial histological change. Eur Rev Med Pharmacol Sci 13(6):431–442Google Scholar
- 29.Latini R, Staszewsky L, Sun J-L et al (2013) Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research trial. Am Heart J 166(5):935–940.e1. https://doi.org/10.1016/j.ahj.2013.08.012 CrossRefGoogle Scholar